Research ArticleCancer

Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer

See allHide authors and affiliations

Science Translational Medicine  18 Sep 2019:
Vol. 11, Issue 510, eaaw7999
DOI: 10.1126/scitranslmed.aaw7999

Log in to view full text

Log in through your institution

Log in through your institution

Stay Connected to Science Translational Medicine

Navigate This Article